Back to today’s briefing

Story perspectives

Novo Nordisk Shares Dive as Eli Lilly's Drug Shines

4/22/2025

42 8

Summary

Novo Nordisk's Decline

Novo Nordisk's stock plummeted more than 7% as Eli Lilly unveiled promising trial results for its oral obesity drug, orforglipron, which rivals Novo's Ozempic in weight loss and blood sugar management. With the GLP-1 market expected to soar to $130 billion by the decade's end, Novo faces mounting pressure to expedite its own oral treatment developments.

Summary

Eli Lilly's Obesity Breakthrough

Eli Lilly's launch of Tirzepatide, known as Mounjaro, in India is a game-changer in the fight against obesity. This groundbreaking drug, which aids in weight loss and diabetes management, comes at an astonishing 80% lower price than in the U.S. However, the challenge of affordability persists as the Indian anti-obesity market is set to soar to $2.6 billion, reflecting a rising demand for effective solutions.

History

Historical Context

Eli Lilly's recent success with tirzepatide mirrors the competitive landscape of the 2000s when GLP-1 drugs emerged. The approval of exenatide in 2005 sparked a race among pharmaceutical companies, leading to a lucrative market. Today's rivalry between Lilly and Novo Nordisk highlights the ongoing evolution in obesity and diabetes treatments.

1 of 3

Novo Nordisk's Decline

Novo Nordisk's stock plummeted more than 7% as Eli Lilly unveiled promising trial results for its oral obesity drug, orforglipron, which rivals Novo's Ozempic in weight loss and blood sugar management. With the GLP-1 market expected to soar to $130 billion by the decade's end, Novo faces mounting pressure to expedite its own oral treatment developments.

1 / 3